Use case webinar: Insights that inform preclinical safety programs
Learn how extracted drug safety data from FDA/EMA drug approval documents can provide information to address potential clinical risks earlier in preclinical studies. A case study where comparative data from drugs with different molecular targets that modulate the same protein indicated in cancer proliferation is used to inform preclinical drug safety program for drug candidates in the same class. Clinical observations of adverse events will be explored with particular attention to cardiac observations found in PharmaPendium®.
- Precedent drug data can be leverage to inform preclinical dose range studies
- Export and transform data for use in analytical models in several simple steps
- Leverage the extensive and relevant extracted data to save time
Tue, May 19, 2015 10:00 AM - 11:00 AM EDT